scholarly journals Neutralizing interleukin-13 increases skin microbial diversity: results from a Phase 3, randomized, double-blind, placebo-controlled trial of tralokinumab in adult patients with atopic dermatitis

2021 ◽  
Vol 5 (6) ◽  
pp. s56
Author(s):  
Thomas Bieber ◽  
Lisa Beck ◽  
Andrew Pink ◽  
Hidehisa Saeki ◽  
Lawrence Eichenfeld ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Microbial Diversity ◽  
Controlled Trial ◽  
Adult Patients ◽  
Phase 3 ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Interleukin 13

N/A

scholarly journals Specifically Targeting Interleukin-13 with Tralokinumab Improved Sleep in Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Trials in Patients with Atopic Dermatitis

2021 ◽  
Vol 5 (1) ◽  
pp. s9
Author(s):  
Jonathan Silverberg ◽  
Sebastien Barbarot ◽  
Melinda Gooderham ◽  
Jan Simon ◽  
Eric Simpson ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Controlled Trials ◽  
Phase 3 ◽  
Two Phase ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Interleukin 13

Abstract not available.

IP 1184. ZX008 (Fenfluramine) in Dravet’s Syndrome: First Results of a Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial

2018 ◽  
Author(s):  
Tilman Polster ◽  
Lieven Lagae ◽  
Joseph Sullivan ◽  
Ulrich Brandl ◽  
Arne Herting ◽  
...  
Keyword(s):  
Controlled Trial ◽  
Phase 3 ◽  
Double Blind ◽  
Double Blind Placebo ◽  
First Results

929g Efficacy and safety of prucalopride in men with chronic constipation: a phase 3, randomized, double-blind, placebo-controlled trial

2014 ◽  
Vol 146 (5) ◽  
pp. S-160 ◽  
Author(s):  
Yan Yiannakou ◽  
Michel Bouchoucha ◽  
Ingolf Schiefke ◽  
Hubert Piessevaux ◽  
Rafal Filip ◽  
...  
Keyword(s):  
Chronic Constipation ◽  
Controlled Trial ◽  
Efficacy And Safety ◽  
Phase 3 ◽  
Double Blind ◽  
Double Blind Placebo
Sign in / Sign up

Export Citation Format

Share Document